Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 12/2014

01-12-2014 | Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Bone as an Endocrine Organ Relevant to Diabetes

Authors: Sarah L. Booth, Amanda J. Centi, Caren Gundberg

Published in: Current Diabetes Reports | Issue 12/2014

Login to get access

Abstract

There are well-established associations between diabetes and fracture risk and yet the mechanism underlying these associations are controversial. Guided by a series of mouse studies, a specific form of the bone protein, osteocalcin, was proposed to be the mechanistic link between these two chronic diseases. Translation to humans initially appeared elusive in part because serum concentrations of osteocalcin are a biomarker of bone turnover and not necessarily specific to the biology of this protein. The suitability of the mouse model for the study of osteocalcin as a therapeutic target also appears ambiguous. With greater discrimination of the different forms of osteocalcin present in circulation and inclusion of multiple measures of bone turnover, evidence currently does not support osteocalcin as a protein critical to the diabetes and fracture association in humans.
Literature
1.
Morrison LB, Bogan IK. Bone development in diabetic children: a roentgen study. Am J Med Sci. 1927;174:313–8.CrossRef
2.
Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann Intern Med. 2014;160:517–25.PubMedCrossRef
3.
4.
Saito M, Kida Y, Kato S, Marumo K. Diabetes, collagen, and bone quality. Curr Osteoporos Rep. 2014;12:181–8.PubMedCrossRef
5.
Pan H, Wu N, Yang T, He W. Association between bone mineral density and type 1 diabetes mellitus: a meta-analysis of cross-sectional studies. Diabetes Metab Res Rev. 2014. in press.
6.
Ogata N, Chikazu D, Kubota N, Terauchi Y, Tobe K, Azuma Y, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest. 2000;105:935–43.PubMedCentralPubMedCrossRef
7.
Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495–505.PubMedCrossRef
8.
Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 2009;25:1057–72.PubMedCrossRef
9.
Akin O, Erkaya S, Clinic MO, Education N. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density. Gynecol Endocrinol. 2003;17(1):19–29.PubMedCrossRef
10.•
Schwartz AV, Schafer AL, Grey A, Vittinghoff E, Palermo L, Lui L-YL, et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res. 2013;28:1348–54. This multi-cohort study demonstrates that disruption of bone turnover (which in turn would decrease circulating total and uncarboxylated osteocalcin) has no effect on glucose metabolism.PubMedCrossRef
11.
Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab. 2008;19:161–6.PubMedCrossRef
12.•
Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013;9:43–55. This review is an in-depth review of the issues related to the theory of osteocalcin in human glucose metabolism.PubMedCrossRef
13.
Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481:314–20.PubMedCrossRef
14.
15.
Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci. 2008;105:5266–70.PubMedCentralPubMedCrossRef
16.
Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50:568–75.PubMedCentralPubMedCrossRef
17.
Nakao M, Nishiuchi Y, Nakata M, Kimura T, Sakakibara S. Synthesis of human osteocalcins: gamma-carboxyglutamic acid at position 17 is essential for a calcium-dependent conformational transition. Pept Res. 1994;7:171–4.PubMed
18.
Cairns JR, Price PA. Direct demonstration that the vitamin K-dependent bone Gla protein is incompletely gamma-carboxylated in humans. J Bone Miner Res. 1994;9:1989–97.PubMedCrossRef
19.
Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142:296–308.PubMedCentralPubMedCrossRef
20.
Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142:309–19.PubMedCentralPubMedCrossRef
21.
Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res. 2011;26:677–80.PubMedCrossRef
22.
Rosen CJ, Motyl KJ. No bones about it: insulin modulates skeletal remodeling. Cell. 2010;142:198–200.PubMedCrossRef
23.
Yoshikawa Y, Kode A, Xu L, Mosialou I, Silva BC, Ferron M, et al. Genetic evidence points to an osteocalcin-independent influence of osteoblasts on energy metabolism. J Bone Miner Res. 2011;26:2012–25.PubMedCentralPubMedCrossRef
24.
Wei J, Ferron M, Clarke CJ, Hannun YA, Jiang H, Blaner WS, et al. Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest. 2014;124:1781–93.PubMedCentralCrossRef
25.
Brennan-speranza TC, Henneicke H, Gasparini SJ, Blankenstein KI, Heinevetter U, Cogger VC, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest. 2012;122(11):4172–89.PubMedCentralPubMedCrossRef
26.
27.•
Riddle RC, Frey JL, Tomlinson RE, Ferron M, Li Y, Digirolamo DJ, et al. Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis. Mol Cell Biol. 2014;34:1850–62. This study proposes a model by which osteocalcin may influence glucose metabolism via the tumor suppressor Tsc2.PubMedCentralPubMedCrossRef
28.
Rowe GC, Choi CS, Neff L, Horne WC, Shulman GI, Baron R. Increased energy expenditure and insulin sensitivity in the high bone mass DeltaFosB transgenic mice. Endocrinology. 2009;150:135–43.PubMedCentralPubMedCrossRef
29.
Haffa A, Krueger D, Bruner J, Engelke J, Gundberg C, Akhter M, et al. Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J Bone Miner Res. 2000;15:872–8.PubMedCrossRef
30.
Shea MK, Gundberg CM, Meigs JB, Dallal GE, Saltzman E, Yoshida M, et al. Gamma-carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr. 2009;90:1230–5.PubMedCentralPubMedCrossRef
31.
Iki M, Tamaki J, Fujita Y, Kouda K, Yura A, Kadowaki E, et al. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int. 2012;23:761–70.PubMedCrossRef
32.
Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab. 2009;94:827–32.PubMedCentralPubMedCrossRef
33.
Saleem U, Mosley Jr TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arteriosler Thromb Vasc Biol. 2010;30:1474–8.CrossRef
34.
Gravenstein KS, Napora JK, Short RG, Ramachandran R, Carlson OD, Metter EJ, et al. Cross-sectional evidence of a signaling pathway from bone homeostasis to glucose metabolism. J Clin Endocrinol Metab. 2011;96:E884–90.PubMedCentralPubMedCrossRef
35.
Wieczorek-Baranowska A, Nowak A, Pilaczyńska-Szcześniak Ł. Osteocalcin and glucose metabolism in postmenopausal women subjected to aerobic training program for 8 weeks. Metabolism. 2012;61:542–5.PubMedCrossRef
36.
Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between obesity, metabolic risks and serum osteocalcin level in postmenopausal women. Gynecol Endocrinol. 2012;28:472–7.PubMedCrossRef
37.
Karlsson MK, Kindblom JM, Ohlsson C. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res. 2009;24(5):785–91.PubMedCrossRef
38.
Hwang YC, Jeong IK, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev. 2009;25:768–72.PubMedCrossRef
39.
Lucey AJ, Paschos GK, Thorsdottir I, Martínéz JA, Cashman KD, Kiely M. Young overweight and obese women with lower circulating osteocalcin concentrations exhibit higher insulin resistance and concentrations of C-reactive protein. Nutr Res. 2013;33:67–75.PubMedCrossRef
40.•
Gower BA, Pollock NK, Casazza K, Clemens TL, Goree LL, Granger WM. Associations of total and undercarboxylated osteocalcin with peripheral and hepatic insulin sensitivity and beta-cell function in overweight adults. J Clin Endocrinol Metab. 2013;98:E1173–80. This study demonstrates that multiple markers of bone turnover are related to glucose metabolism, which would suggest that associations between osteocalcin and glucose metabolism may be indicative of a larger role of bone in diabetes.PubMedCentralPubMedCrossRef
41.
Bao Y, Ma X, Yang R, Wang F, Hao Y, Dou J, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab. 2013;98:345–51.PubMedCrossRef
42.
Lu C, Ivaska KK, Alen M, Wang Q, Törmäkangas T, Xu L, et al. Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women. J Clin Endocrinol Metab. 2012;97:4106–14.PubMedCrossRef
43.
Polgreen LE, Jacobs DR, Nathan BM, Steinberger J, Moran A, Sinaiko AR. Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity. 2012;20:2194–201.PubMedCentralPubMedCrossRef
44.
Díaz-López A, Bulló M, Juanola-Falgarona M, Martínez-González MA, Estruch R, Covas M-I, et al. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case–control study. J Clin Endocrinol Metab. 2013;98:4524–31.PubMedCrossRef
45.
Paldánius PM, Ivaska KK, Hovi P, Andersson S, Eriksson JG, Väänänen K, et al. Total and carboxylated osteocalcin associate with insulin levels in young adults born with normal or very low birth weight. PLoS One. 2013;8:e63036.PubMedCentralPubMedCrossRef
46.
Foresta C, Strapazzon G, De Toni L, Gianesello L, Calcagno A, Pilon C, et al. Evidence for osteocalcin production by adipose tissue and its role in human metabolism. J Clin Endocrinol Metab. 2010;95:3502–6.PubMedCrossRef
47.
Iglesias P, Arrieta F, Piñera M, Botella-Carretero JI, Balsa JA, Zamarrón I, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol. 2011;75:184–8.CrossRef
48.
Movahed A, Larijani B, Nabipour I, Kalantarhormozi M, Asadipooya K, Vahdat K, et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. J Bone Miner Metab. 2012;30:683–91.PubMedCrossRef
49.
Hwang Y-C, Jee J-H, Jeong I-K, Ahn KJ, Chung HY, Lee M-K. Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study. Diabetes Care. 2012;35:1919–24.PubMedCentralPubMedCrossRef
50.
Truong JT, Fu X, Saltzman E, Al Rajabi A, Dallal GE, Gundberg CM, et al. Age group and sex do not influence responses of vitamin K biomarkers to changes in dietary vitamin K. J Nutr. 2012;142:936–41.PubMedCentralPubMedCrossRef
51.
Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, Gundberg C, et al. Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care. 2008;31:2092–6.PubMedCentralPubMedCrossRef
52.
53.
Choi HJ, Yu J, Choi H, An JH, Kim SW, Park KS, et al. Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial. Diabetes Care. 2011;34:e147.PubMedCentralPubMedCrossRef
54.
Ibarrola-Jurado N, Salas-Salvado J, Martinez-Gonzalez MA, Bullo M. Dietary phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of cardiovascular disease. Am J Clin Nutr. 2012;96:1113–8.PubMedCrossRef
55.
Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol. 2012;8:81–91.CrossRef
56.
Vestergaard P. Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif Tissue Int. 2011;89:265–70.PubMedCrossRef
57.
Hong S-H, Koo J-W, Hwang JK, Hwang Y-C, Jeong I-K, Ahn KJ, et al. Changes in serum osteocalcin are not associated with changes in glucose or insulin for osteoporotic patients treated with bisphosphonate. J Bone Metab. 2013;20:37–41.PubMedCentralPubMedCrossRef
58.
Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care. 1998;21:1589–95.PubMedCrossRef
59.
Kanaya AM. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1.PubMedCrossRef
60.
Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47:1175–87.PubMedCrossRef
61.
Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther. 2003;25:919–30.PubMedCrossRef
62.
Anastasilakis AD, Efstathiadou Z, Plevraki E, Koukoulis GN, Slavakis A, Kita M, et al. Effect of exogenous intermittent recombinant human PTH 1–34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity. Horm Metab Res. 2008;40:702–7.PubMedCrossRef
63.
64.
Hoang QQ, Sicheri F, Howard AJ, Yang DSC. Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature. 2003;425:977–80.PubMedCrossRef
65.
Arbour NC, Darwish HM, DeLuca HF. Transcriptional control of the osteocalcin gene by 1,25-dihydroxyvitamin D-2 and its 24-epimer in rat osteosarcoma cells. Biochim Biophys Acta. 1995;1263:147–53.PubMedCrossRef
66.
Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;1:1091–3.PubMedCrossRef
67.
Karsenty G. Bone endocrine regulation of energy metabolism and male reproduction. C R Biol. 2011;334:720–4.PubMedCrossRef
68.•
Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, et al. Endocrine regulation of male fertility by the skeleton. Cell. 2011;144:796–809. This study proposed that osteocalcin may have a role in fertility in male mice via the GPRC6A receptor.PubMedCentralPubMedCrossRef
69.
Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J Bone Miner Res. 2011;26:1680–3.PubMedCrossRef
70.•
Jacobsen SE, Nørskov-Lauritsen L, Thomsen ARB, Smajilovic S, Wellendorph P, Larsson NHP, et al. Delineation of the GPRC6A receptor signaling pathways using a mammalian cell line stably expressing the receptor. J Pharmacol Exp Ther. 2013;347:298–309. This study refutes the theory the osteocalcin may be associated with via the GPRC6A receptor.PubMedCrossRef
71.
Bolland MJ, Grey A, Horne AM, Reid IR. Testosterone levels following decreases in serum osteocalcin. Calcif Tissue Int. 2013;93:133–6.PubMedCrossRef
72.
Hannemann A, Breer S, Wallaschofski H, Nauck M, Baumeister SE, Barvencik F, et al. Osteocalcin is associated with testosterone in the general population and selected patients with bone disorders. Andrology. 2013;1:469–74.PubMedCrossRef
Metadata
Title
Bone as an Endocrine Organ Relevant to Diabetes
Authors
Sarah L. Booth
Amanda J. Centi
Caren Gundberg
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 12/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0556-3

Other articles of this Issue 12/2014

Current Diabetes Reports 12/2014 Go to the issue

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Extracellular Matrix Components in the Pathogenesis of Type 1 Diabetes

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (EM Venditti, Section Editor)

Community Health Worker Interventions for Latinos With Type 2 Diabetes: a Systematic Review of Randomized Controlled Trials

Psychosocial Aspects (KK Hood, Section Editor)

Shared Neurobiological Pathways Between Type 2 Diabetes and Depressive Symptoms: a Review of Morphological and Neurocognitive Findings

Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

The Charcot Foot as a Complication of Diabetic Neuropathy

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (EM Venditti, Section Editor)

Lifestyle Interventions to Reduce Diabetes and Cardiovascular Disease Risk Among Children

Transplantation (A Pileggi, Section Editor)

Stem Cell Therapy to Treat Heart Ischaemia: Implications for Diabetes Cardiovascular Complications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits